At GoBroad Healthcare Group, we are dedicated to pioneering the field of cellular immunotherapy, particularly for patients battling leukemia. As a leading healthcare provider in China, we specialize in delivering comprehensive cancer treatments that cater to individuals across all age groups. Our commitment to innovation and excellence in cellular immunotherapy empowers us to offer advanced therapies that significantly enhance patient outcomes.

Innovative CAR-T Therapy Options

One of our primary focuses in cellular immunotherapy is the development of CAR-T (Chimeric Antigen Receptor T-cell) therapies. We provide a variety of single-target CAR-T therapies that specifically target antigens such as CD19, CD20, CD22, CD7, CD5, GPRC5D, and CLL1. These targeted approaches harness the body’s immune system to effectively combat leukemia cells, leading to improved treatment responses. By utilizing cellular immunotherapy, we are able to offer personalized treatment plans that maximize efficacy while minimizing side effects.

Sequential Dual-Target CAR-T Cell Therapy

For patients with refractory or relapsed acute leukemia, we have pioneered sequential dual-target CAR-T cell therapy. This innovative approach allows us to target multiple antigens simultaneously, enhancing the chances of overcoming resistance to treatment. By leveraging the power of cellular immunotherapy, we can provide a more robust defense against leukemia, offering hope to patients who have limited options. At GoBroad, we continuously strive to improve our therapies, ensuring that our patients receive the most effective and cutting-edge treatments available.

Comprehensive Hematologic Stem Cell Transplantation

In addition to our cellular immunotherapy options, we offer hematologic stem cell transplantation (HSCT) for patients with refractory or relapsed acute leukemia. Our transplantation program is designed to accommodate a wide age range, from infants to those 74 years old. With thousands of successful cases completed, we explore innovative transplantation methods that achieve high success rates while minimizing complications. This comprehensive approach to leukemia treatment exemplifies our commitment to providing holistic care through cellular immunotherapy and advanced transplantation techniques.

Conclusion

At GoBroad Healthcare Group, we are proud to be at the forefront of cellular immunotherapy for leukemia treatment. Our innovative CAR-T therapies, sequential dual-target options, and comprehensive hematologic stem cell transplantation program reflect our dedication to improving patient outcomes. As we continue to advance the field of cellular immunotherapy, our focus remains on delivering personalized, effective, and compassionate care to all patients. Together, we are working towards a brighter future in the fight against leukemia, ensuring that every patient has access to the best possible treatment options.